Home Cart Sign in  
Chemical Structure| 6217-54-5 Chemical Structure| 6217-54-5
Chemical Structure| 6217-54-5

*Storage: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C.

Docosahexaenoic Acid

CAS No.: 6217-54-5

Docosahexaenoic Acid (DHA) is an omega-3 fatty acid that regulates various cell signaling pathways, with an IC50 value of 5 μM. DHA exhibits anti-inflammatory, cardiovascular protective, and neuroprotective effects and is widely used in research on cardiovascular diseases and neurodegenerative disorders.

Synonyms: DHA;Cervonic acid;Doconexent

4.5 *For Research Use Only !

Cat. No.: A267106 Purity: 95%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
100mg łÍǶÊÊ In Stock Inquiry Login
250mg łÿî¶ÊÊ Inquiry Inquiry Login
1g łó§¶ÊÊ Inquiry Inquiry Login
5g łËÊî¶ÊÊ Inquiry Inquiry Login
10g ł§Íó¶ÊÊ Inquiry Inquiry Login
25g łďÿÿ¶ÊÊ Inquiry Inquiry Login

Please Login or Create an Account to: See VIP prices and availability

  • 100mg

    łÍǶÊÊ

  • 250mg

    łÿî¶ÊÊ

  • 1g

    łó§¶ÊÊ

  • 5g

    łËÊî¶ÊÊ

  • 10g

    ł§Íó¶ÊÊ

  • 25g

    łďÿÿ¶ÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations      Show More

Lee, Jin ; Park, Hyun-Ah ; Shin, Kyung-Chul , et al.

Abstract: Resolvin D5 (RvD5), 7S,17S-dihydroxy-4Z,8E,10Z,13Z,15E,19Z-docosahexaenoic acid (DHA) is a specialized pro-resolving mediator (SPM) generated in human macrophages. It is implicated in the resolution of inflammation and synthesized using an inefficient chem. process. Here, DHA-enriched oil hydrolyzate was prepared from oils by lipase with resin treatment and solvent extraction The reaction factors on the biotransformation of oil hydrolyzate into RvD5 were optimized using Escherichia coli expressing arachidonate double-oxygenating 15S-lipoxygenase. After optimization, the cells converted 5.0 mM (1.64 g/L) DHA in oil hydrolyzate into 4.0 mM (1.44 g/L) RvD5 in a bioreactor for 3.0 h, which was 15-fold higher than that in a flask before optimization, and RvD5 with a purity of > 97% was prepared from reaction solution by treatments of resins. This is the first trial for the production of C22-dihydroxy fatty acid using a bioreactor. This study will contribute to the large-scale production of SPMs from oils.

Keywords: Lipoxygenase ; Resolvin D5 ; Docosahexaenoic acid-enriched oil hydrolysate ; Biotransformation ; Bioreactor

Purchased from AmBeed: ; ; ;

Lee, Hyejin ; Yoon, Hye-Ran ;

Abstract: We developed and validated a fast, sensitive, and accurate anal. method using ultra high-pressure liquid chromatog.-electrospray ionization tandem mass spectrometry (UHPLC-ESI-MS/MS) for simultaneous extraction and quantification of 5 targeted omega fatty acids on human dried serum spots. MS/MS was performed with multiple reaction monitoring (MRM) mode under neg. electrospray ionization. We targeted omega fatty acids which are likely to have a pos. effect on various inflammatory reactions such as asthma, chronic obstructive pulmonary diseases and rheumatoid arthritis. If applicable, it is necessary to determine them as asthma biomarkers for intervention and public health. The coefficient of determination (r2) of calibration curve exhibited a good linear relationship between 0.9942 and 0.9963 in a range of 0.05-5μg mL-1. The anal. method was validated with excellent sensitivity (limit of detection; 0.005-0.01μg mL-1, limit of quantification; 0.03-0.1μg mL) that allows targeted analyses of omega fatty acids. We obtained the recoveries of 92.6 to 110.4% (RSD, 0.2-9.6%) for intraday and 92.6 to 107.6% (RSD, 1.4-7.0%) for interday. Clin. correlation between the healthy subjects and asthmatic patients sera was evaluated with the ratio of omega-3/omega-6 fatty acids. The developed method combines the advantages of easy handling dried filter paper and UHPLC-MS/MS for effectiveness of extraction and analyses step. We evaluated the validation for the quantification and applicability of human serum as a possible role of asthma biomarkers.

Keywords: Omega fatty acids ; Dried human serum spot ; UHPLC-MS ; MS ; Negative ionization ; Asthma

Purchased from AmBeed: ; ; ; ;

Hyejin Lee ; Hye-Ran Yoon ;

Abstract: Omega fatty acids play an important role as biomarkers of chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, and inflammatory bowel disease. The purpose of our study was to develop a new analytical method for the detection of omega fatty acids from dried serum spots. We developed an ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry (UHPLC-ESI-MS/MS)-based method in the multiple reaction monitoring (MRM) mode with negative ionization. The detected MRM transitions for five omega fatty acids are as follow: α-linolenic acid (m/z=277.20→277.20), eicosapentaenoic acid (m/z=301.10→257.30), docosahexaenoic acid (m/z=327.00→283.15), arachidonic acid (m/z=303.20→259.25), and docosapentaenoic acid (m/z= 329.10→285.25). The calibration curve showed an excellent linearity within 0.1-2.5 μg/mL range (R2=0.9947~0.9994). The analytical methods howed excellent sensitivity (LOD: 0.005-0.01 μg/mL, LOQ: 0.03-0.1 μg/mL), which would allow for the targeted analyses of omega fatty acids. The recoveries of the omega fatty acid from the dried serum spots were 92.6%-110.4% (RSD: ±0.2%-9.6%) and the retention time was within 5 min. This improved method offers rapid and sensitive quantification of omega fatty acids on dried serum spots using a small volume of serum and is expected to be applied to various biological specimens.

Keywords: Omega fatty acid ; Dried serum spot ; Negative ionization ; UPLC-MS/MS ; Asthma

Purchased from AmBeed: ; ;

Product Details of [ 6217-54-5 ]

CAS No. :6217-54-5
Formula : C22H32O2
M.W : 328.49
SMILES Code : CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
Synonyms :
DHA;Cervonic acid;Doconexent
MDL No. :MFCD00065722

Safety of [ 6217-54-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H227-H315-H319-H335-H413
Precautionary Statements:P210-P261-P264-P271-P273-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P370+P378-P403+P233-P403+P235-P405-P501

Calculated chemistry of [ 6217-54-5 ] Show Less

Physicochemical Properties

Num. heavy atoms 24
Num. arom. heavy atoms 0
Fraction Csp3 0.41
Num. rotatable bonds 14
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 106.8
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

37.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

None
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

None
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

6.55
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

None
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

None
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

None

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

None
Solubility None mg/ml ; None mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

None
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

None
Solubility None mg/ml ; None mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

None
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

None
Solubility None mg/ml ; None mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

None

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

None
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

None
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

None
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

None
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

None
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

None
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

None
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

None
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

None cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

None
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

None
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

None
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

None
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

None

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

None alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

None alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW< td="">
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

None

Application In Synthesis [ 6217-54-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 6217-54-5 ]

[ 6217-54-5 ] Synthesis Path-Downstream   1~4

  • 1
  • [ 6217-54-5 ]
  • [ 255735-88-7 ]
  • [ 1204318-28-4 ]
YieldReaction ConditionsOperation in experiment
70% With triethylamine; HATU; In acetonitrile; at 0 - 20℃; Example 21; Preparation of N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidopropyl)-2-hydroxybenzamide (14); To a solution of tert-butyl 2-aminopropylcarbamate (1.06 g, 6.09 mmol, prepared as previously described), DHA (2.0 g, 6.09 mmol) and Et3N (1.7 mL, 12.8 mmol) in CH3CN (40 mL) at 0° C. was added HATU (2.31 g, 6.09 mmol). The mixture was stirred (RT, 16 h) and concentrated under reduced pressure. The residue was diluted with brine (100 mL) and extracted with EA (2.x.100 mL). The combined organic layers were washed with saturated NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel, eluting with EA-PE (0-25percent) to afford tert-butyl 2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidopropylcarbamate (2.1 g, 70percent) as a light yellow oil. Mass calculated for C30H48N2O3=484.71; found: [M+H]+=485.6.
  • 2
  • [ 6217-54-5 ]
  • [ 2934-05-6 ]
  • [ 1224157-47-4 ]
  • 3
  • [ 6217-54-5 ]
  • [ 263162-13-6 ]
  • [ 1333067-38-1 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; HATU; In acetonitrile; at 20℃; for 2h; <strong>[263162-13-6]tert-butyl 2-((2-aminoethyl)(methyl)amino)ethylcarbamate</strong> (430 mg, 1.98 mmol) was taken up in 10 mL of CH3CN along with (4Z,7Z,10Z,13Z,16Z,19Z)-docosa- 4,7,10,13,16,19-hexaenoic acid (DHA, 650 mg, 1.98 mmol), HATU (750 mg, 2.2 mmol) and DIEA (0.550 mL). The resulting reaction mixture was stirred at room temperature for 2 h and then diluted with EtOAc (40 mL). The organic layer was washed with brine, dried (Na2S04) and concentrated under reduced pressure. Purification by chromatography (95% CH2C12, 5% MeOH) afforded 400 mg of the Boc-protected intermediate. This material was taken up in 3 mL of 4 M HC1 in dioxane and allowed to stir at room temperature for 10 min. The reaction mixture was concentrated under reduced pressure to afford the HCl salt of (4Z,7Z, 10Z, 13Z, 16Z, 19Z)-N-(2-((2-aminoethyl)(methyl)amino)ethyl)docosa- 4,7,10,13,16,19-hexaenamide.
With N-ethyl-N,N-diisopropylamine; HATU; at 20℃; for 2h; <strong>[263162-13-6]tert-butyl 2-((2-aminoethyl)(methyl)amino)ethylcarbamate</strong> (430 mg, 1.98 mmol) was taken up in 10 mL of CH3CN along with (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19- hexaenoic acid (DHA, 650 mg, 1.98 mmol), HATU (750 mg, 2.2 mmol) and DIEA (0.550 mL). The resulting reaction mixture was stirred at room temperature for 2 h and then diluted with EtOAc (40 mL). The organic layer was washed with brine, dried (Na2S04) and concentrated under reduced pressure. Purification by chromatography (95% CH2CI2, 5% MeOH) afforded 400 mg of the Boc-protected intermediate. This material was taken up in 3 mL of 4 M HCl in dioxane and allowed to stir at room temperature for 10 min.
  • 4
  • [ 6217-54-5 ]
  • [ 22808-73-7 ]
  • (4Z,7Z,10Z,13Z,16Z,19Z)-N-((4-methoxycarbonyl)phenylsulfonyl)docosa-4,7,10,13,16,19-hexaenamide [ No CAS ]
 

Related Products

Historical Records

Technical Information

Categories